SCHEMBL176509

SCHEMBL176509

C=C(C)C(=O)OCCC(COP(=O)(O)O)[N+](C)(C)C

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.40
THRB P10828 1/20 0.38
ALDH1A1 P00352 1/20 0.33
PGK1 P00558 1/20 0.33
PGK2 P07205 1/20 0.33
PGD P52209 4/20 0.32
ENPP2 Q13822 3/20 0.31
LPAR6 P43657 1/20 0.31
LPAR1 Q92633 1/20 0.31
LPAR4 Q99677 1/20 0.31
LPAR5 Q9H1C0 1/20 0.31
LPAR2 Q9HBW0 1/20 0.31
LPAR3 Q9UBY5 1/20 0.31
BTN3A1 O00481 1/20 0.30
POLB P06746 1/20 0.30
APEX1 P27695 1/20 0.30
HTT P42858 1/20 0.30
TDP1 Q9NUW8 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2944692 0.92 THRB (0.44) TSHRTHRBALDH1A1PGK1PGK2
SCHEMBL541439 0.92 TSHR (0.42) TSHRTHRBALDH1A1PGK1PGK2
SCHEMBL541226 0.91 TSHR (0.44) TSHRTHRBALDH1A1ENPP2LPAR6
SCHEMBL2038860 0.90 THRB (0.39) TSHRTHRBALDH1A1LPAR1LPAR2
SCHEMBL541451 0.89 TSHR (0.47) TSHRTHRBENPP2LPAR6LPAR1
SCHEMBL6851650 0.89 TSHR (0.38) TSHRTHRBALDH1A1
SCHEMBL20582579 0.86 THRB (0.40) TSHRTHRBALDH1A1PGK1PGK2
SCHEMBL16737919 0.86 TSHR (0.39) TSHRTHRBALDH1A1LPAR1LPAR2
SCHEMBL28637235 0.84 TSHR (0.40) TSHRTHRBENPP2LPAR6LPAR1
SCHEMBL3677974 0.83 TSHR (0.42) TSHRTHRBALDH1A1LPAR1LPAR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 315 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240189121-A1 ANTI-THROMBOGENIC MEDICAL DEVICES AND METHODS COVIDIEN LP 2024-06-13 US claimed
EP-3666299-B1 ANTI-THROMBOGENIC MEDICAL DEVICES AND METHODS COVIDIEN LP (US) 2024-05-15 EP claimed
US-11903850-B2 Anti-thrombogenic medical devices and methods COVIDIEN LP (US) 2024-02-20 US claimed
WO-2023021885-A1 ELECTROLYTIC SOLUTION FOR CAPACITOR AND CAPACITOR カーリットホールディングス株式会社 2023-02-23 WO claimed
WO-2023013368-A1 METHOD FOR PRODUCING SOLID ELECTROLYTIC CAPACITOR カーリットホールディングス株式会社 2023-02-09 WO claimed
US-20230036800-A1 ANTI-THROMBOGENIC MEDICAL DEVICES AND METHODS COVIDIEN LP 2023-02-02 US claimed
US-11406514-B2 Anti-thrombogenic medical devices and methods COVIDIEN LP (US) 2022-08-09 US claimed
US-20220227954-A1 POLYMERIC SURFACE HAVING REDUCED BIOMOLECULE ADHESION TO THERMOPLASTIC ARTICLES OF SUCH SUBSTRATE OAKTREE FUND ADMINISTRATION, LLC 2022-07-21 US claimed
US-11369497-B2 Anti-thrombogenic medical devices and methods COVIDIEN LP (US) 2022-06-28 US claimed
EP-3862384-A2 POLYMERIC SUBSTRATE WITH A SURFACE HAVING REDUCED BIOMOLECULE ADHESION, AND THERMOPLASTIC ARTICLES OF SUCH SUBSTRATE SiO2 Medical Products, Inc. (US) 2021-08-11 EP claimed
US-20100203004-A1 COSMETIC COMPOSITION CONTAINING A TENSIONING AGENT AND AN ACRYLIC POLYMER L'OREAL (FR) 2010-08-12 US claimed
EP-2205197-A1 COSMETIC COMPOSITION CONTAINING A TENSIONING AGENT AND AN ACRYLIC POLYMER L'Oreal (FR) 2010-07-14 EP claimed
US-20100094339-A1 COATING COMPOSITIONS COVIDIEN LP 2010-04-15 US claimed
US-20090304770-A1 POLYMER BIOCOMPATIBLES UK LIMITED (GB) 2009-12-10 US claimed
EP-2120824-A1 COATING COMPOSITIONS Tyco Healthcare Group LP (US) 2009-11-25 EP claimed
WO-2009056545-A1 COSMETIC COMPOSITION CONTAINING A TENSIONING AGENT AND AN ACRYLIC POLYMER L'OREAL (FR) 2009-05-07 WO claimed
WO-2008143654-A1 COATING COMPOSITIONS TYCO HEALTHCARE GROUP LP (US) 2008-11-27 WO claimed
EP-1764078-B1 Microcapsules with aqueous core and their use in cosmetic compositions OREAL (FR) 2008-05-14 EP claimed
EP-1764078-A1 Microcapsules with aqueous core and their use in cosmetic compositions L'OREAL (FR) 2007-03-21 EP claimed
US-6828028-B1 Having surface treated with copolymer of such as ring opened glycidyl methacrylate and 2-(methacryloyloxy)ethyl-2-(tri-methylammonio)ethylphosphate; lubricity, blood compatible, safe, stable, durable NOF CORPORATION (JP) 2004-12-07 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090304770-A1 POLYMER MLX, BMX, PUF60 TSHR 2143/4885THRB 704/4885ALDH1A1 3167/4885
US-20100203004-A1 COSMETIC COMPOSITION CONTAINING A TENSIONING AGENT AND AN ACRYLIC POLYMER PHOSPHO1, CUTA, SGMS1 TSHR 3000/4885THRB 3607/4885ALDH1A1 4031/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.